– The only Korean company announces guest speakers invited to take part in ISCT 2019
– Discuss national regulations, approval programs and commercialization strategies

MEDIPOST announced on August 30 that it will present its clinical experience in Korea and overseas at the International Society for Cell and Gene Therapy (ISCT) 2019 Annual Meeting (5.29 ~ 6.1) in Melbourne, Australia.

ISCT, a Canadian-based International Cell and Gene Therapy Association, was established in 1992 and leads the development of related research through conducting active exchanges with regulatory and academic institutions and industry partners. Representatives from more than 50 countries attended the ISCT 2019 annual meeting, and MEDIPOST was the only Korean company to be invited as a guest speaker.

Lee Seung-jin, CEO of MEDIPOST USA, presented his company’s clinical experience on May 30 in a session centered on the topic of the “Regulatory Effects on the Global Commercialization of Cell and Gene Therapy Products” and would have the panel discussion with the representatives of licensing authorities in three countries: KFDA, Japan PDMA, and Australia TGA.

He said, “we will announce Korean clinical trials and the approval experience of CARTISTEM^® for knee osteoarthritis cartilage regeneration treatment, US clinical cases and next-phase clinical trial plans, and the clinical plans and strategies in Japan and China,” and “discuss the various regulations and approval programs at regulatory agencies and their impact on global commercialization strategies.”